NuVasive Inc. Reaches New 12-Month High at $34.73 (NUVA)
NuVasive (NASDAQ:NUVA)’s share price reached a new 52-week high on Tuesday, Stock Ratings Network.com reports. The company traded as high as $34.73 and last traded at $34.64, with a volume of 537,818 shares traded. The stock had previously closed at $33.02.
A number of research firms have recently commented on NUVA. Analysts at Zacks downgraded shares of NuVasive from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday, January 2nd. They now have a $35.40 price target on the stock. Separately, analysts at Barclays raised their price target on shares of NuVasive from $30.00 to $32.00 in a research note to investors on Monday, December 2nd. They now have an “equal weight” rating on the stock. Finally, analysts at RBC Capital raised their price target on shares of NuVasive from $31.00 to $35.00 in a research note to investors on Friday, November 15th. They now have a “sector perform” rating on the stock. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the stock. NuVasive presently has a consensus rating of “Hold” and an average target price of $29.15.
In other NuVasive news, SVP Craig Hunsaker sold 4,275 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $32.10, for a total transaction of $137,227.50. Following the completion of the transaction, the senior vice president now directly owns 24,980 shares in the company, valued at approximately $801,858. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
NuVasive has a 1-year low of $15.71 and a 1-year high of $33.91. The stock’s 50-day moving average is $32.53 and its 200-day moving average is $27.29. The company’s market cap is $1.561 billion.
NuVasive (NASDAQ:NUVA) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.15. The company had revenue of $169.20 million for the quarter, compared to the consensus estimate of $158.30 million. During the same quarter in the previous year, the company posted $0.23 earnings per share. The company’s revenue for the quarter was up 14.0% on a year-over-year basis. Analysts expect that NuVasive will post $1.14 EPS for the current fiscal year.
NuVasive, Inc (NASDAQ:NUVA) is a medical device company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.